Hutchmed (China) Limited Exercise of Share Options by a Director (4948I)

TIDMHCM

RNS Number : 4948I

Hutchmed (China) Limited

07 August 2023

Exercise of Share Options by a Director

Hong Kong, Shanghai & Florham Park, NJ - Monday, August 7, 2023: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM, HKEX: 13) today announces that it has issued a total of 3,000,000 ordinary shares of US$0.10 each ("Ordinary Shares") following the exercise of share options by Dr Weiguo Su, Executive Director, Chief Executive Officer and Chief Scientific Officer, at an exercise price of GBP1.97 per Ordinary Share on August 7, 2023 (the "Exercise of Options").

Following the Exercise of Options, Dr Su is beneficially interested in 5,000,000 Ordinary Shares (Note 1) and 632,505 American Depositary Shares ("ADSs") (Note 2) , representing 0.94% of the current issued share capital of the Company.

Notes:

1. 5,000,000 Ordinary Shares included (i) 3,000,000 Ordinary Shares currently held by Dr Su, and (ii) share options for 2,000,000 Ordinary Shares granted under Share Option Scheme

2. 632,505 ADSs included (i) 143,518 ADSs currently held by Dr Su, (ii) share options for 395,442 ADSs granted under Share Option Scheme and (iii) 93,545 ADSs as beneficiary of a trust under long term incentive plan.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 
 1       Details of the person discharging managerial responsibilities/person closely associated 
 
   a)      Name                                Dr Weiguo Su 
        ----------------------------------  ------------------------------------------------------------------------ 
 2       Reason for the notification 
        ------------------------------------------------------------------------------------------------------------ 
 
   a)      Position/status                    Executive Director, Chief Executive Officer and Chief Scientific 
                                              Officer 
        ----------------------------------  ------------------------------------------------------------------------ 
 
   b)      Initial notification/Amendment      Initial notification 
        ----------------------------------  ------------------------------------------------------------------------ 
 3       Details of the issuer, emission allowance market participant, auction platform, auctioneer 
          or auction monitor 
        ------------------------------------------------------------------------------------------------------------ 
 
   a)      Name                                HUTCHMED (China) Limited 
        ----------------------------------  ------------------------------------------------------------------------ 
 
   b)      LEI                                 2138006X34YDQ6OBYE79 
        ----------------------------------  ------------------------------------------------------------------------ 
 4       Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
          each type of transaction; (iii) each date; and (iv) each place where transactions have been 
          conducted 
        ------------------------------------------------------------------------------------------------------------ 
 
   a)     Description of the financial         Ordinary Shares of US$0.10 each 
          instrument, type of instrument 
 
          Identification code                  DI ISIN: KYG4672N1198 
        ----------------------------------  ------------------------------------------------------------------------ 
 
   b)      Nature of the transaction          Exercise of share options for 3,000,000 Ordinary Shares on August 7, 
                                              2023 at exercise price 
                                              of GBP1.97 per Ordinary Share 
        ----------------------------------  ------------------------------------------------------------------------ 
 
                                             Price(s)                            Volume(s) 
                                            ----------------------------------  ---------------------------------- 
                                             GBP1.97                             3,000,000 
                                            ----------------------------------  ---------------------------------- 
 c)      Price(s) and volume(s) 
        ----------------------------------  ----------------------------------  ---------------------------------- 
 
   d)      Aggregated information              Aggregated volume: 3,000,000 Ordinary Shares 
           -  Aggregated volume                Price information: GBP5,910,000 
           -  Price 
        ----------------------------------  ------------------------------------------------------------------------ 
 
   e)      Date of the transaction             2023-08-07 
        ----------------------------------  ------------------------------------------------------------------------ 
 
   f)      Place of the transaction            Outside a trading venue 
        ----------------------------------  ------------------------------------------------------------------------ 
 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission, on AIM and on HKEX. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                            [phone] 
  Annie Cheng, Vice President                                [phone] 
 
Media Enquiries 
  Americas - Brad Miles,                                     [phone] (Mobile) / bmiles@s oleburystrat .com 
   Solebury Strategic Communications 
  Europe - Ben Atwell / Alex Shaw,                           [phone] / [phone] (Mobile) / +44 7779 
   FTI Consulting                                            545 055 (Mobile) / [e-mail] 
  Asia - Zhou Yi, Brunswick                                  [phone] (Mobile) / [e-mail] 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure 
   Gordon                                                    [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGZGGRNNNGFZG

(END) Dow Jones Newswires

August 07, 2023 04:30 ET (08:30 GMT)